Contingency intervention for reduction of cannabis in early psychosis

Conditions

Psychotic illnesses including schizophrenia, schizo-affective disorder and bipolar disorder with psychotic symptoms Mental and Behavioural Disorders Mental and behavioural disorders due to use of cannabinoids

Sheridan Rains L, Marston L, Hinton M, Marwaha S, Craig T, Fowler D, King M, Omar RZ, McCrone P, Spencer J, Taylor J, Colman S, Harder C, Gilbert E, Randhawa A, Labuschagne K, Jones C, Stefanidou T, Christoforou M, Craig M, Strang J, Weaver T, Johnson S.

2019-08-1521 citations

10.1186/s12916-019-1395-5

A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT

Sonia Johnson, Luke Sheridan Rains, Steven Marwaha, John Strang, Tom Craig et al. (15 authors)

Health Technology Assessment2019-08-0127 citations

10.3310/hta23450

A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial.

Johnson S, Sheridan Rains L, Marwaha S, Strang J, Craig T, Weaver T, McCrone P, King M, Fowler D, Pilling S, Marston L, Omar RZ, Craig M, Hinton M.

2016-10-226 citations

10.1186/s13063-016-1620-x

Interventions

Experimental group: Contingency management involving voucher rewards for abstinence demonstrated by urinalysis together with psychoeducation delivered by care coordinators. Control gr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Under the care of an early intervention service for psychosis 2. Diagnostic criteria for EIS entry require a first psychotic episode significantly impairing functioning and lasting more than a week 3. Problematic cannabis use is operationalised as having used cannabis at least once in at least 12 of the previous 24 weeks 4. Aged 18-39, male and female participants

Exclusion criteria

Exclusion criteria: Insufficient English to complete the study assessments

Design outcomes

Primary

Measure	Time frame
Time to relapse is assessed as admission to acute mental health care over 18 months	—

Secondary

Measure	Time frame
1. Presence of cannabis on urinalysis at 3 months and at 18 months of follow up 2. Positive symptom severity measured by Positive and Negative Syndrome Scale (PANSS) at 3 months and 18 months 3. Engagement in work or study is assessed by participant self report at 3 months and 18 months	—

Countries

United Kingdom

Outcome results

None listed